Enveda reports presentation of ENV-294 findings at AAD
Enveda →Enveda reported that results from its Phase 1b atopic dermatitis study of ENV-294 had been presented at the American Academy of Dermatology Innovation Academy in New York. The company also announced acceptance of an oral presentation for the subsequent EADV Congress in Vienna. The release characterized the candidate as an investigational oral therapy and described exploratory efficacy observations alongside the study’s principal safety objective. These findings concerned an early clinical study rather than regulatory approval or established commercial treatment. The announcement provided a conference update to previously disclosed results and outlined additional scientific communication planned for the same development program.